Clinical trials: Tace
Unresectable Intrahepatic Cholangiocarcinoma
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC.
- Trial name
- NCT02994251
- Testing
- gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
Combination Treatment for Advanced Liver Cancer
The purpose of this study is to determine whether TACE combined endovascular stent implantation confers a survival benefit over TACE alone.
- Trial name
- NCT02149771
- Testing
- chemoembolization, endovascular stents implantation, iodine-125 seed strand implantation
- Where
- China
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma (HCC)
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of a combination therapy involving TACE, sintilimab, bevacizumab, and ipilimumab N01 for the treatment of advanced hepatocellular…
- Trial name
- NCT07422753
- Testing
- CTLA-4 Antibody(ipilimumab N01)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intrahepatic Cholangiocarcinoma
A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
At present, for advanced Intrahepatic Cholangiocarcinoma（ICC）, the effect of single treatment is not good.So far, superselective drug-eluting bead transarterial chemoembolization（DEB-TACE） is a good method for the treatment of…
- Trial name
- CCGLC-005 (NCT05236699)
- Testing
- DEB-TACE combined with Surufatinib and Camrelizumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma
Percutaneous, image-guided tumor ablation has evolved as a genuine alternative for the treatment of unresectable hepatocellular carcinoma.
- Trial name
- CEAL (NCT00807300)
- Testing
- CT-guided brachytherapy, transarterial chemoembolization
- Where
- Germany
- Volunteers
- 77 people
- Sponsor
- University of Magdeburg
Hepatocellular Carcinoma
Surefire Institutional DEB-TACE
The purpose of this study is to determine the feasibility and safety of the Surefire Infusion System (SIS) for delivery of Drug Eluting Beads Transcatheter Chemoembolization (DEB-TACE) in the HCC population.
- Trial name
- NCT03211598
- Testing
- TACE with Surefire
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Alexander Kim
Liver Cancer
Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer
The clinical trail of Cinobufacini combined with TACE on primary liver cancer.The trail is randomized controled.Patients are diagnosed primary liver cancer based on pathology or cell biology.They are randomized into 2 groups:both…
- Trial name
- NCT03843229
- Testing
- Cinobufacini injection, Transarterial Chemoembolization(TACE), cinobufacini tablet
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Advanced Hepatocellular Carcinoma
TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.
This study will evaluate the safety and effect of transcatheter arterial chemoembolization (TACE)combined with percutaneous transhepatic PD-1 knockout engineered T cell infusion in the Paitents with advanced hepatocellular…
- Trial name
- NCT04417764
- Testing
- Transcatheter arterial chemoembolization, PD-1 knockout engineered T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Central South University
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
There is an unmet need for patients with intermediate stage hepatocellular carcinoma (HCC). It is known that local tumor ablation can increase tumor immunogenicity by releasing tumor associated antigens, potentially increasing…
- Trial name
- NCT05776875
- Testing
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma
The purpose of this real-world study is to evaluate the safety and efficacy of lipiodol-TACE with idarubicin for hepatocellular carcinoma.
- Trial name
- NCT05280444
- Testing
- Idarubicin Hydrochloride for Injection
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Liver Neoplasms
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
This single-center, prospective study evaluates the therapeutic outcomes of saline-augmented bipolar radiofrequency ablation (RFA) with twin internally cooled-perfusion (TICP) electrodes for treating recurrent hepatocellular…
- Trial name
- ERFA (NCT07192172)
- Testing
- Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
This is a single-arm, open-label, phase II clinical trial. Patients with unresectable hepatocellular carcinoma (HCC) who are eligible for lenvatinib treatment will receive partial transarterial chemoembolization (TACE) targeting…
- Trial name
- Pearl (NCT07827807)
- Testing
- Lenvatinib, Partial transarterial chemoembolization (TACE)
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCE001 (NCT04975932)
- Testing
- TACE+ICIs, TACE
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma Non-resectable, HCC
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
- Trial name
- IMMUWIN (NCT04522544)
- Testing
- Tremelimumab, Durvalumab, Y-90 SIRT
- Where
- 11 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Abstract of Research Proposal Radiofrequency ablation (RFA) has been proved to be a curative treatment with minimal invasiveness and high efficacy for small hepatocellular carcinoma (HCC) that is generally defined as maximal…
- Trial name
- NCT01858207
- Testing
- Transcatheter Arterial Chemoembolization, Radiofrequency ablation, Doxorubicin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Shi-Ming Lin
Liver Cancer, Pain Postoperative
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
This phase III, randomized, prospective clinical study, aiming to compare the analgesic effects of celecoxib, parecoxib, and oxycodone in patients with inoperable hepatic carcinoma undergoing TACE procedure in postoperative pain…
- Trial name
- NCT03059238
- Testing
- Celecoxib 200mg oral capsule, parecoxib sodium, controlled-release oxycodone
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Sun Yat-sen University
HCC, Transarterial Chemoembolization
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1…
- Conditions
- HCC, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Regorafenib
- Trial name
- NCT05025592
- Testing
- Regorafenib, cTACE/DEB-TACE-HAIC
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Carcinoma, Hepatocellular
Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC
Transcatheter arterial chemoembolization (TACE) is a key palliative treatment for patients with inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT02338297
- Testing
- TACE, EGM, PVA
- Where
- 2 sites in China
- Volunteers
- 236 people
- Sponsor
- Nanjing Medical University
Liver Tumor
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
To explore the objective effectiveness and safety of TACE combined with Lenvatinib in the treatment of advanced liver cancer. After successful down-stage, radical microwave ablation was further performed.
- Trial name
- NCT05555316
- Testing
- TACE combined with Lenvatinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University